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Title 
Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model 
Abstract 
Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s 
disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, 
transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after 
induced expression of amyloid-β. GC- and LC MS-based platforms determined a total of 157 
differential features. Some of these were identified using in-house (GC-MS) or public libraries 
(LC-MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far 
better suited to metabolomics studies than most other model systems, the accordance of these 
findings with vertebrate literature is promising and argues for further use of C. elegans as a 
model of human pathology in the study of AD.  
Keywords: Metabolomics, Metabolic profiling, Caenorhabditis elegans, Alzheimer’s disease, 
Amyloid-β  
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Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for over 70% of all cases 
worldwide (World Alzheimer’s Report, 2009). In addition, AD causes a severe social and financial 
impact on patients and their environment. The number of patients worldwide with AD is estimated at a 
current 24 million, a number that will have tripled by 2050 (World Health Organization, 2012). AD is a 
progressive disease with a long preclinical phase of 10-15 years (Tarawneh & Holtzman, 2012), which 
creates opportunities for a biomarker detection approach. AD is characterized by inflammation, 
neuronal loss, intracellular aggregation of the protein tau and extracellular plaques of the peptide 
amyloid-β. Amyloid-β, generated from the amyloid-β precursor protein (APP), is mainly processed in 
an anti-amyloidogenic manner (Haass et al., 2012). However, in AD patients, APP is overly processed 
according to the amyloidogenic pathway, which leads to the release of aggregating amyloid peptides 
(Haass et al., 2012). Additionally, the microtubule stabilizing protein tau becomes hyperphosphorylated 
and forms intracellular neurofibrillary tangles (Mandelkow & Mandelkow, 2012). Since there is no 
cure for AD, it is becoming increasingly more important to find early pathological markers which could 
easily be measured by a non-invasive method, prior to the emergence of clinical symptoms.  
Current biomarkers in cerebrospinal fluid (CSF) are the amount of total tau, phosphorylated tau, 
amyloid-β (Blennow et al., 2012) and the 42/40 ratio of amyloid-β (Wiltfang et al., 2007). Although 
CSF removal is an uncomfortable, invasive procedure, it is often used to diagnose AD. A range of 
imaging techniques has been developed over the last couple of years to improve the diagnosis of AD 
(Johnson et al., 2012). Despite the improvement of fluid biomarker discovery and imaging techniques, 
AD is typically diagnosed when patients start displaying cognitive impairment. Recently, researchers 
have started turning towards metabolomics as a promising method to assist in the search for early 
biomarkers of AD (Trushina & Mielke, 2013).  
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Metabolomics uses a range of sensitive and complementary analytical platforms to study the levels of 
small molecules in cells, tissues, bio-fluids and entire organisms, referred to as the metabolome 
(Roessner & Bowne, 2009). Because gene expression, protein activity and environment all exert certain 
influences on the metabolome, metabolomic readouts closely reflect cellular processes and provide 
highly accurate snapshots of an organism’s state. Two platforms are mainly used: gas or liquid 
chromatographic separation hyphenated to mass spectrometry (GC-MS and LC-MS) and nuclear 
magnetic resonance (NMR)-based spectroscopy (Temmerman et al., 2013). Current literature on 
metabolomics related to AD is rather limited and a distinct set of metabolic markers has not yet been 
discovered (Graham et al., 2013; Kaddurah-Daouk et al., 2013; Kaddurah-Daouk et al., 2011; Lin et al., 
2013; Mapstone et al., 2014; Motsinger-Reif et al., 2013; Orešič et al., 2011; Salek et al., 2010; Sato et 
al., 2012; Trushina et al., 2013). This may in part be due to the underlying heterogeneity of the sample 
groups. To improve this issue, the use of a model can be advantageous. 
Model organisms are used to investigate the function of certain factors in a simplified system in 
comparison to humans. Many model organisms have been used in the study of AD (e.g. Saccharomyces 
cerevisiae (De Vos et al., 2011), Caenorhabditis elegans (Link, 2006), Drosophila melanogaster 
(Iijima-Ando & Iijima, 2010), Mus musculus (Elder et al., 2010)). Here, C. elegans was chosen because 
it allows for the most stringent level of experimental control in the study of multicellular organisms. 
This addresses the importance of minimizing unwanted variation, especially necessary when using 
sensitive techniques like metabolomics, biomarker discovery and compound screens. A transgenic, 
temperature-sensitive strain expressing amyloid-β in the neurons was selected, enabling time- and site- 
controlled expression of the transgene. Such strains have already proven their value in AD research in 
the study of amyloid-β aggregation (Fay et al., 1995), gene expression (Link, 2003), toxicity screening 
(Dostal & Link, 2010), learning behavior (Dosanjh et al., 2010) and proteomic changes (Boyd-Kimball 
et al., 2006). In this study, a metabolic fingerprint was generated of a well-established (Boyd-Kimball 
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et al., 2006; Dosanjh et al., 2010; Dostal & Link, 2010; Link, 1995;  Link, 2003) transgenic AD strain 
in order to monitor metabolic changes due to expression of amyloid-β. Both non-targeted GC-MS and 
LC-MS analyses were performed, ensuring a broad detection of the extracted metabolites. LC-MS 
analysis was further refined using two different chromatographic separation methods (reversed phase 
(RP) and aqueous normal phase (ANP)). Because C. elegans can be used to screen a large amount of 
metabolites in a relatively short time, these findings will form the basis of future testing of drug 
efficiency and the mode-of-action during AD progression. 
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Materials and Methods 
C. elegans culture and sampling 
Temperature-sensitive transgenic (CL2355) and control (PD8120) strains were kindly provided by 
Professor Christopher Link (University of Colorado at Boulder, USA). Strains were cultured at 16 °C 
on standard nematode growth medium (NGM) agar seeded with Escherichia coli OP50 bacteria 
(Brenner, 1974). CL2355 (smg-1(cc546);dvIs50 [pCL45 (Psnb-1::Aβ1-42::3' UTR(long) + Pmtl-
2::GFP]) drives pan-neuronal expression of the peptide Aβ1-42 under control of the C. elegans 
synaptobrevin (snb-1) promoter. The expression can be induced by a temperature upshift from 16 °C to 
23 °C (Fig. 1), as a result of the temperature-sensitive smg-1
ts
 background, also present in the control 
strain, in which nonsense-mediated mRNA decay (NMD) is disturbed upon temperature upshift (Link, 
2003).  
Age-synchronized transgenic and control strains were cultured in liquid medium with E. coli K12 as a 
food source, for 34 h at 16 °C. Food availability was held constant (OD600 = 1.68) by adding bacteria 
twice a day during culturing. After 34 h, both strains were shifted to 23 °C, inducing the expression of 
Aβ1-42 in the AD strain only. Another 30 h later, worms were collected by pelleting on ice (Fig. 1). The 
removal of bacteria and debris was carried out using a sucrose-flotation (60 % sucrose). After 
collection, the worms were washed with S-buffer (Brenner, 1974) for 5 times and partitioned into 
aliquots of maximum 0.3 ml per tube (Precellys lysing kit, Bertin Technologies). The aliquots were 
snap frozen in liquid nitrogen and stored at -80 °C.  
A total of 14 biologically independent samples for each condition were used. As negative controls, 
three samples of each condition without temperature upshift were produced, in addition to four 
supernatant samples. The latter were used to establish the metabolite baseline of the medium: features 
extracted from these negative controls were omitted from all further sample analyses. 
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Extraction 
We opted for an extraction using ice-cold 80% methanol, as described earlier for C. elegans (Geier et 
al., 2011). Ice-cold methanol, containing an external standard (
13
C6-sorbitol (0.5 mg/ml), 
13
C5
15
N-
Valine (0.5 mg/ml), 2-aminoanthracene (0.25 mg/ml) and pentafluorobenzoic acid (0.25 mg/ml)), was 
added to the worm pellet until 80 % methanol was reached. All samples were homogenized at low 
temperature (Precellys 24, Bertin Technologies; 2x 30 s, 4800 rpm, -20 °C) to avoid potential 
metabolite degradation. Subsequently, samples were held on ice for 15 min and were then centrifuged 
for 15 min at 13,000 rpm. Supernatants were transferred to new Eppendorf tubes and pellets were re-
extracted with 80 % methanol. To avoid protein contamination, all samples were filtered using a 3 kDa 
cutoff filter (Amicon Ultra UFC500308). Both supernatants were combined and re-divided into 3 
aliquots for GC-MS and LC-MS (RP and ANP coupled to quadrupole time of flight mass spectrometry 
(Q-TOF)) analyses. These aliquots were dried using a speed-vacuum concentrator and then stored at -
80 °C until analysis. 
GC-MS analysis 
The dried samples were redissolved in 10 μL of 30 mg ml-1 methoxyamine hydrochloride in pyridine 
and derivatised at 37°C for 120 min with mixing at 500 rpm. The samples were then treated for 30 min 
with 20 μl N,O-bis-(trimethylsilyl)trifluoroacetamide (BSTFA) and 2.0 μl retention time standard 
mixture [0.029% (v/v) n-dodecane, n-pentadecane, n-nonadecane, n-docosane, n-octacosane, n-
dotriacontane, n-hexatriacontane dissolved in pyridine] with mixing at 500 rpm. Each derivatised 
sample was allowed to rest for 60 min prior to injection. 
 
Samples (1 μl) were injected into a GC-MS system comprised of a Gerstel 2.5.2 autosampler, a 7890A 
Agilent gas chromatograph and a 7000 Agilent triple-quadrupole MS (Agilent). The MS was adjusted 
according to the manufacturer’s recommendations using tris-(perfluorobutyl)-amine (CF43). The GC 
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was performed on a 30 m VF-5MS column with 0.2 μm film thickness and a 10 m Integra guard 
column (J & W, Agilent). The injection temperature was set at 250°C, the MS transfer line at 280°C, 
the ion source adjusted to 250°C and the quadrupole at 150ºC. Helium was used as the carrier gas at a 
flow rate of 1.0 ml min
-1
. For the polar metabolite analysis, the following temperature program was 
used; start at injection 70°C, a hold for 1 min, followed by a 7°C min
-1
 oven temperature ramp to 
325°C and a final 6 min heating at 325°C in which the data was acquired in full-scan mode. Both 
chromatograms and mass spectra were evaluated using AMDIS (NIST, www.chemdata.nist.gov) and 
Agilent MassHunter Workstation Software, Quantitative Analysis, Version B.05.00/Build 5.0.291.0 for 
GCMS. Mass spectra of eluting compounds were identified using NIST08 database and the in-house 
Metabolomics Australia mass spectral library. All matching mass spectra were additionally verified by 
determination of the retention time and index in comparison to those of standard substances. Every six 
samples, a pooled instrument control sample consisting of 54 standard compounds was run to evaluate 
potential retention time shifts and loss in sensitivity (Supplemental Fig. 1). As can be expected for GC, 
all quality control runs overlapped clearly and no significant retetion time shift was present. A 
significant loss in sensitivity was not observed. It can therefore be taken into account by normalization 
strategies (see below). None of the differential and identified metabolites had multiple TMS 
derivatives. All data were exported as a comma separated value file for further data analysis.  
 
LC-MS analysis 
Materials 
LC-MS grade formic acid and ammonium acetate were purchased from Sigma-Aldrich (Sydney, 
Australia). Deionized water (18.2 MΩ) was used throughout all experiments. HPLC grade methanol 
and acetonitrile (ACN) were purchased from Burdick and Jackson (Ajax, Sydney, Australia). Reversed 
phase (RP) chromatography was done using a Zorbax Eclipse XDB-C18m 2.1mm × 100mm, 1.8 μm 
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(Agilent, Santa Clara, CA, USA). The Cogent diamond hybrid 2.1 mm × 100 mm, 4 μm particle size 
ANP column was purchased from MicroSolv Technology (Brisbane, Australia).  
LC-MS system 
In this experiment an Agilent 1200 series HPLC was used (Santa Clara, CA, USA) comprising of a 
vacuum degasser, binary pump, thermostated auto sampler and column compartment. Extraction 
procedures, solvent gradients, concentration sample, column conditions and mass spectrometer settings 
were optimized using pooled samples; reflecting an averaged sample of the overall experiment. The 
settings found to be optimal for C. elegans metabolites were then used for all subsequent runs. For RP 
chromatography, a 10 min linear gradient of 95:5 water/ACN to 5:95 water/ACN at 0.4 ml/min was 
used while the column temperature was held at 50 °C. Both mobile phases contained 0.1 % formic 
acid. For the complementary ANP procedure, solvents were made with uttermost care and the system 
was thoroughly flushed to ensure a proper separation of the metabolites. The organic mobile phase 
solvent (B) was composed of 90 % ACN with 0.1 % (w/v) ammonium acetate and 0.1 % acetic acid. 
The aqueous mobile phase (A) was composed of 100 % deionized water with 0.1 % (w/v) ammonium 
acetate and 0.1 % acetic acid (pH 3.4). The column flow-rate was 0.4 ml/min and column temperature 
was kept at 50 °C. The optimal gradient started at 100 % B then linearly decreased to 40 % B over 10 
min, followed by a 1 min hold at 40 % B. The column was then re-equilibrated at 100 % B for 6 min
20
. 
For both modes, a washing step was added every run to control for unwanted carry-over. Every six 
samples, a pooled biological control sample was run to evaluate potential retention time shifts and 
variations in mass accuracy (Supplemental Fig. 2). Retention time shifts were never bigger than 0.1 
min and the average deviation of the mass accuracy always remained lower than 1.78 ppm 
(Supplemental Table 1).  
The mass spectrometer used was an Agilent 6520 QTOF MS system (Santa Clara, CA, USA) with a 
dual spray ESI source. The conditions for the source were: nebulizer pressure of 45 psi, gas flow-rate 
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of 10 l/min, gas temperature 300 °C, capillary voltage of 4 kV and skimmer 65 V. Measurements were 
performed in the extended dynamic range mode (m/z range of 70-1700 amu), both in positive and 
negative ion mode and collecting centroid data. Data were exported as .mzdata to be further analyzed in 
MZmine 2.10 (Pluskal et al., 2010). In addition, to increase the accuracy of the identification, high 
resolution (70 000), more accurate (< 3 ppm) MS and MS/MS data of differential features were 
obtained by running pooled samples using a ‘top 10’ method on a Q Exactive Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific).  
LC-MS data analysis was performed using MZmine 2.10 (Pluskal et al., 2010). After centroid peak 
detection, all data points above the noise level were processed as pairs of m/z and intensity values. Peak 
lists were created using the chromatogram builder. The chromatograms were deconvoluted and isotopic 
peaks were grouped. Finally, peak lists were aligned using the random sample consensus (RANSAC) 
alignment method (Pluskal et al., 2010). After filtering and gap filling, the data matrix was exported as 
a comma separated value file for further processing. All parameters were optimized for each data 
collection mode. LC-MS identification was performed using public databases (HMDB, KEGG and 
Metlin). Based on mass value (Δppm < 10 ppm) and accurate mass (Δppm < 3 ppm) features were 
matched against these databases. 
Data analysis 
Statistical analysis was performed using the R package metabolomics (De Livera et al., 2013) and the 
MetaboAnalyst webserver (Xia et al., 2012). An initial log2 transformation was applied to obtain a 
normal distribution. After this transformation, the dataset was median normalized and a combination of 
multivariate and univariate statistical tests was performed. Principal components analysis (PCA), an 
unsupervised explorative data analysis method, was performed to evaluate the overall variance in the 
obtained datasets. Similarly, supervised partial-least squares discriminant analysis (PLS-DA) was 
conducted to better explore the variance differentiating the two experimental conditions (AD vs. 
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control). Variable Importance in Projection (VIP) scores represent which of the features contribute 
most to the differentiation of the experimental groups in PLS-DA analysis. Significant differences in 
abundance of individual features between conditions were evaluated using a standard t-test.All p values 
were adjusted according to the Benjamini & Hochberg principle to take false discovery rate into 
account.  
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Results and discussion 
There are already a few reports on the metabolome of human AD cerebrospinal fluid (CSF) (Kaddurah-
Daouk et al., 2013; Kaddurah-Daouk et al., 2011; Orešič et al., 2011; Trushina et al., 2013) (Graham et 
al., 2013), plasma (Trushina et al., 2013) and of CSF reflecting the pathological progress from mild 
cognitive impairment to AD (Orešič et al., 2011). Despite these research efforts, working with human 
samples implies a high level of inherent variation (age, sex, diet, medical history, etc), which may mask 
relevant results. Therefore, use of more controllable model organisms can help to deliver a more 
delineated fingerprint, which can then be used for targeted studies in patients. Based on this reasoning, 
metabolic analyses on transgenic AD mice  (Fukuhara et al., 2013; Graham et al., 2013; Salek et al., 
2010) revealed a widespread perturbation of metabolism in different tissues and bio fluids. In the same 
vein, here C. elegans was used to discover metabolic changes due to AD by generating a metabolic 
fingerprint of a transgenic, pan-neuronal amyloid-β strain. 
C. elegans is a suitable model organism to screen multiple drug compounds efficiently and has the 
potential to discover markers for diseases in a cheap, fast and controlled manner. Metabolomics has 
proven its value for C. elegans research (Fuchs et al., 2010; Hughes et al., 2009), although profiling, to 
our knowledge has not been performed with transgenic C. elegans AD models. We used a metabolic 
approach to evaluate the C. elegans amyloid-β AD model, relying on a combination of GC-MS and 
four LC-MS platforms (ANP-MS and RP-MS, each acquired in positive and negative ion mode).  
Overall feature detection and sample separation 
A clear chromatographic separation was achieved for all approaches (Fig. 2), resulting in a final total of 
157 differential features (p value < 0.05) (Table 1). Mean normalized abundance and standard deviation 
of all samples in all modes were determined (Supplemental Table 2). 
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Unsupervised multivariate statistics did not always succeed in separating the experimental groups 
(Supplemental Figures 3 and 4). Principal components analysis (PCA) generally resulted in a modest 
separation of the experimental groups. Poor PCA plot separations are also the case in similar studies 
(Lin et al., 2013; Trushina et al., 2013), but these rely on less controllable model systems. This could 
possibly be explained by the sample type: as opposed to human CSF or brain tissue samples, we used 
whole-mount extracts for analysis. Therefore, the behavior of some differentiating features might yet 
be diluted or masked. Even though the central nervous system is the actual site of interest, it can 
currently not be distinguished from other tissues in C. elegans. Nevertheless, partial least squares 
discriminant analysis (PLS-DA) in combination with variable importance in projection tables 
(Supplemental Figures 5-11) illustrate that observed differential features considerably contribute to the 
separation of the two groups. Evaluation of volcano plots, showing the significance and fold-changes of 
all data points, was also indicative of a defined set of robustly differential features (Supplemental 
Figures 12-16).  
 
Differential features as a result of AD pathology in C. elegans 
For the GC approach every peak corresponding to a feature was manually selected and compared to a 
library of reference compounds, resulting in a final list of 76 unique compounds. Upon differential 
analysis, only a few known metabolites were significantly altered in AD conditions as compared to 
controls (Table 2). Of all features, 38% could not be identified because of a lack of corresponding 
library entry (in-house or NIST08) (Supplemental Fig. 17). 
LC-MS data were acquired in positive and negative ion mode, each combined with two separation 
methods (RP and ANP) (Fig. 2). As such, an elaborate spectrum of metabolites could be examined. RP 
and ANP methodologies are suitable for differing sub-populations of the metabolome, explaining why 
only a few features were seen in both approaches. Features detected in both ANP and RP delivered 
similar readouts (Supplemental Figure 18), providing corroborative evidence for the observed results. 
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LC-MS profiling resulted in a detection of 2096 to 11039 features, depending on the acquisition mode 
(ANP-MS negative mode: 2096; ANP-MS positive mode: 4424; RP-MS negative mode: 5992; RP-MS 
positive mode: 11039). It is immediately clear that the RP negative mode dataset shows the highest 
amount of differential features (Table 1 and Supplemental Table 3). By looking in further detail to this 
mode, many features were observed to co-elute and have similar fold changes. This may imply that a 
single metabolite may be present as a number of adducts which could lead to deconvolution of several 
related features. Therefore, an adduct search using the CAMERA package was performed on RP 
negative mode data (Kuhl et al., 2012). Approximately 15% of the features were identified as adducts. 
The most significant differential (p value < 0.01) features are presented in Table 3, remaining 
differential results are shown in supplemental Table 3. In sum, LC-MS analysis revealed 149 
differential features, mostly detected from reversed phase LC in combination with negative ion mode. 
By comparing the obtained results with research on AD LC-MS metabolomics literature (Lin et al., 
2013; Trushina et al., 2013), some putative features were found with matching mass (Δppm < 50 ppm) 
and similar fold changes (Fig. 1, Table 3 and Supplemental Table 3). These confirm that the same 
reactions might be (de)activated in C. elegans when comparing to mouse or human. Since most 
metabolomics experiments conducted to date relied on targeted methods, it can be assumed that this 
number is an underestimation of the actual correspondence (i.e. when comparing to other non-targeted 
studies). In addition, more corresponding features can be expected if not only amyloid-β1-42, but also 
the protein tau would be expressed in the C. elegans model. Amyloid-β1-42 probably only induces a part 
of the metabolic changes which occur in AD (Ittner & Götz, 2011), therefore, adding tau might better 
reflect the biochemical changes related to AD progression. 
 
Known metabolic markers of AD 
In our C. elegans experiments, several putatively identified metabolites correspond to metabolites 
previously associated with AD pathology (Table 2 and 3). These are of special interest for further 
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discussion. A higher level of allantoin was observed in our experiments in C. elegans, matching 
observations in human plasma and mice (Fukuhara et al., 2013; Zitnanová et al., 2004). Allantoin is 
produced in a non-enzymatic oxidation reaction when uric acid is exposed to reactive oxygen species 
(ROS). This is further supported by evaluation of the GC-MS VIP scores (Supplemental Fig. 7), which 
are high for both uric acid and allantoin itself, indicating these features contribute strongly to the 
differentiation of both conditions. Allantoin is often used as an oxidative marker (Yardim-Akaydin et 
al., 2006). Oxidative stress is a frequently discussed topic in AD research, since it may precede the 
appearance of pathological hallmarks, e.g. senile plaques and neurofibrillary tangles (Perry et al., 
2002). Oxidative stress in AD is probably the result of a disturbed redox balance due to malfunctioning 
of the mitochondria (Zhao & Zhao, 2013). Both amyloid-β and tau can be found in the mitochondria 
where they dysregulate the oxidative phosphorylation system (complex IV and I, respectively)  (Rhein 
et al., 2009), associated with an increased ROS production. This could then indeed set the scene for the 
observed increase in allantoin levels. 
Upon expression of amyloid-β, tyrosine was upregulated in both LC- and GC-MS analyses, indicating 
the robustness of this result. Alterations of the tyrosine pathway in CSF, serum and autopsy-confirmed 
brain tissue of AD patients were also previously observed (Kaddurah-Daouk et al., 2011; Trushina et 
al., 2013). Tyrosine is an important precursor of the neurotransmitter dopamine, and of the 
catecholamines norepinephrine and epinephrine. When dopamine is formed, tyrosine is processed by 
tyrosine hydroxylase (TH). A reduced activity of TH (Trillo et al., 2013) and 
norepinephrine/epinephrine (Kaddurah-Daouk et al., 2011) have been observed in AD patients. The 
here observed upregulation of tyrosine might therefore be due to a reduced activity of TH, but this 
remains to be confirmed.  
A decreased cystathionine concentration was observed after the expression of amyloid-β in C. elegans. 
Polymorphisms in cystathionine beta synthase (CBS), catalyzing the conversion of homocysteine to 
cystathionine, are well-known risk factors for AD (Perluigi & Butterfield, 2012). These gene 
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polymorphisms are known to decrease CBS activity and cause a high concentration of homocysteine 
and a low concentration of cystathionine (Bi et al., 2010), in line with our observations in C. elegans. 
The clear correlations of these identified, differential metabolites with vertebrate AD pathology support 
the robustness of the C. elegans model system. 
  
Long-lived C. elegans exhibit opposite alterations 
Because C. elegans is also a well-established model system for aging research, there is added value in 
comparing information for long-lived, healthy strains with the here used AD strain. This is because the 
latter is hallmarked by a decreased lifespan and impaired learning behavior due to neurodegeneration 
(Dosanjh et al., 2010), therefore displaying opposite phenotypes. Proteomic analysis (Depuydt et al., 
2014) of the long-lived daf-2 mutant revealed an increase in tyrosine catabolism. This contrasts with 
the higher levels of tyrosine observed in the AD model used here. Similarly, a strong upregulation of 
CBS is observed in the long-lived daf-2 mutant (Depuydt et al., 2014), implying increased 
concentrations of cystathionine. This again confirms the molecular basis for the opposite phenotypes. 
As more and more -omics data are becoming available, such comparisons could in the future assist in 
discriminating general, aging-related effects from more AD-specific perturbations. 
 
 
Prospects  
Although our results are promising and some comparisons with human AD pathology could be made, 
elaborate comparison of studies is not straightforward. This has a dual reason: for one, human studies 
rely on very distinct sample types. Brain tissue, on one hand, can only be used from post-mortem 
patients and often suffers from degradation. CSF from patients, on the other hand, is an achievable 
alternative, but implies a change towards indirect results from a biofluid, rather than direct information 
from the affected tissue. In addition, limited effort is made for the complete determination of the 
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metabolic fingerprint. This is readily understood from the set of metabolic markers discussed above, 
which do not (yet) display any clear biological coherence or pathway logic. If we want to accurately 
map the pathological process, complete identified metabolic fingerprints - which represent the 
comprehensive status of all extracted metabolites - should be compared over time in profiling 
experiments. This strategy will allow for the robust discovery of potential biomarker candidates and 
grants an invaluable advantage to complementary compound screens. After administration of a certain 
lead compound, the fingerprint can indicate which (sub)processes are altered. Currently, essential 
information can easily be overlooked due to the partial identification of the fingerprints. Such analyses 
should ideally be performed preclinical, in a controlled model where metabolic fingerprints can be 
identified more easily. 
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Concluding Remarks 
Our results show that C. elegans has the abilities to develop into an amenable model for AD 
metabolomics experiments. The here described set of metabolites provide a blueprint for future 
completion of the AD fingerprint, as such further refining our mechanistic insights into this devastating 
disease. Metabolomic analyses, compound screenings and biomarker discovery require an exceptional 
high level of experimental control. Future experiments with optimized double transgenic worms, 
expressing amyloid-β and tau together, will therefore be invaluable to assist in the advances of 
metabolomics with regards to AD progression. 
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Table legends 
Table 1: Total of differential features in different modes. (LC=Liquid chromatography, RP=reversed 
phase, ANP=aqueous normal phase, GC=gas chromatography)  
 
Table 2: Significant GC-MS (p value <0.05) features with mass identifiers, retention time, p value 
(*adjusted according to the Benjamini & Hochberg principle), Z-factor, fold change and identity. Z-
factor provides a useful tool for comparison and evaluation of the quality of the assay (Zhang, 1999).  
 
Table 3: Features related to AD pathology from LC-MS analysis (p value<0.01). m/z value, retention 
time, p value (*adjusted according to the Benjamini & Hochberg principle), Z-factor, fold change, 
separation-detection mode and putative similarities with literature are provided. For tyrosine, formula 
and adduct ion are also shown. Z-factor provides a useful tool for comparison and evaluation of the 
quality of the assay (Zhang, 1999). Adducts were combined and indicated with ’ ; a confirmed in Lin et 
al. 2013. Accurate mass of tyrosine in Supplemental Table 4. 
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Figure legends 
Fig. 1: Scheme of experimental setup. Both AD model and control strains were cultured for 34 h at 16 
°C. After this period, a temperature upshift to 23 °C was performed, inducing amyloid-β42 expression 
in the AD strain only. Thirty hours later, worms were collected and snap frozen with liquid nitrogen. 
An 80% ice-cold methanol extraction was performed and samples were aliquoted for GC-MS, RP-
QTOF or ANP-QTOF. A) After data-analysis, features that were putatively identified showed a similar 
pattern as seen in previous human AD research. B) Some of our unidentified features could be linked to 
LC-MS AD metabolomics profiling literature.  
 
Fig. 2: Representative UPLC ESI-base peak chromatograms of C. elegans extracts from different 
platforms. X-axis: retention time (from 0-14 minutes), Y-axis: peak intensity (total ion count from 0 to 
8.0E6). 
Figures and Tables 
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Fig, 1 
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Fig, 2 
Differential features different modes 
Method 
Ion 
mode 
Differential features  
LC-MS: RP + 14 
LC-MS: RP - 113 
LC-MS: 
ANP 
+ 21 
LC-MS: 
ANP 
- 1 
GC-MS + 8 
Table 1 
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GC-MS differential features 
Mass 
identifiers 
RT 
p 
value* 
Z-
factor 
Fold 
change 
Identity 
188 15,1 0,0253 -1,75 3,33 Unknown 
314, 329 15,5 0,0253 -3,28 1,93 Unknown 
411 31 0,0253 -6,2 0,56 Unknown 
299 16,2 0,0253 -3,51 1,88 Unknown 
403, 189 17,2 0,0253 -3,04 0,53 Unknown 
264, 279 20,8 0,0253 -3,06 1,83 Allantoin 
278, 245 25,3 0,0253 -3,34 0,54 Cystathionine 
243, 128 15 0,0481 -3,83 1,58 Unknown 
218, 280 21,8 0,0022 -11,09 1,35 Tyrosine 
Table 2 
 
LC-MS differential features 
m/z 
value 
RT 
 p 
value* 
Z-
factor 
Fold 
change 
Mode 
180,065 1,3 0,0446 -2,63 1,36 RP- 
  Identified as Tyrosine (C9H11NO3, [M-H]-)  
173,1108 3,1 0,0017 -1,38 2,11 ANP+ 
131,1159 7 0,0017 -1,07 4,76 ANP+ 
169,0724 7 0,0017 -1,1 3,21 ANP+ 
230,1783 8,1 0,0017 -0,19 7,92 ANP+ 
384,1027 1,4 0,0037 -2,06 0,57 RP- 
509,3433
a
 12,4 0,0037 -1,1 9,54 RP- 
929.6274' 11,6 0,005 -1,35 15,77 RP- 
464.5713' 11,6 0,005 -1,83 5,48 RP- 
366,1274 12,7 0,005 -1,71 9,96 RP- 
929,8786 3,8 0,005 -0,72 4,03 RP- 
114,0901 0,8 0,0052 -1,37 2,91 RP+ 
448,2284 9,7 0,0052 -1,89 2,35 RP+ 
131,1167 0,8 0,0061 -1,36 3,56 RP+ 
362,2059 8,8 0,0061 -2,09 2,56 RP+ 
131,2164 0,8 0,0061 -1,62 2,72 RP+ 
485,1334 4,4 0,0061 -1,3 7,21 RP+ 
516,0773 3,7 0,0061 -1,77 3,87 RP+ 
131,0899 0,8 0,0068 -1,84 2,85 RP+ 
397,2089 8,5 0,0068 -2,05 3,35 RP+ 
173,1239 3 0,0084 -0,69 3,39 ANP+ 
449,1221 8 0,0096 -2,1 6,72 RP- 
Table 3 
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Supplemental information 
 
Supplemental Fig. 1: Quality control process GC-MS. Every six samples, a pooled instrument control 
sample consisting of 54 standard compounds was run to evaluate potential retention time shifts and 
loss in sensitivity. All quality control runs overlapped clearly and no significant retetion time shift was 
present. A disturbing loss in sensitivity was not observed. It can therefore be taken into account by 
normalization strategies. X-axis: retention time, Y-axis: peak intensity. 
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Supplemental Fig. 2: Quality control runs for different LC-Q-TOF modes. Every 6 samples a pooled 
biological control sample was run to verify technical consistency. Retention time shifts were never 
bigger than 0.1 min. Mass accuracy was verified over time (always lower than 1.78 ppm), sensivity 
never dropped more than 15% and was uniform over runs, which is accounted for by normalization. X-
axis: retention time (from 0-14 minutes), Y-axis: peak intensity (total ion count from 0 to 8.0E6). 
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Supplemental Fig. 3: Principal components analysis (PCA) plot of GC-MS data shows no clear 
separation of the control and Alzheimer groups. PCA plots were performed to evaluate the overall 
variance in the obtained datasets. 
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Supplemental Fig. 4: PCA plots of LC-MS data show no clear separation of the control and Alzheimer 
groups. Red circles represent AD samples, green circles represent control samples. PCA plots were 
performed to evaluate the overall variance in the obtained datasets. 
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Supplemental Fig. 5: The supervised partial-least squares discriminant analysis (PLS-DA) of GC-MS 
mode was conducted to better explore the variance differentiating the two experimental conditions (AD 
vs. control). In line with expectations, a better separation of the experimental groups was achieved. 
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Supplemental Fig. 6: The supervised partial-least squares discriminant analysis (PLS-DA) of LC-MS 
data was conducted to better explore the variance differentiating the two experimental conditions (AD 
vs. control). In line with expectations, a better separation of the experimental groups was achieved. 
Red circles represent AD samples, green circles represent control samples. 
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Supplemental Fig. 7: Variable Importance in Projection (VIP) of GC-MS mode. VIP scores indicate the 
importance of a variable in projection using a PLS-DA model. VIP-scores > 1 can be considered as 
good variables in a given model. Differential features are highlighted in red. Retention time is given for 
the unidentified features. Red squares indicate upregulation of this feature in a condition, green 
squares indicate downregulation. 
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Supplemental Fig. 8: Variable Importance in Projection (VIP) of RP-MS positive mode. VIP scores 
indicate the importance of a variable in projection using a PLS DA model. VIP-scores > 1 can be 
considered as good variables in a given model. Differential features are highlighted in red. Red 
squares indicate upregulation of this feature in a condition, green squares indicate downregulation. 
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Supplemental Fig. 9: Variable Importance in Projection (VIP) of RP-MS negative mode. VIP scores 
indicate the importance of a variable in projection using a PLS DA model. VIP-scores > 1 can be 
considered as good variables in a given model. All features shown are also differential. Red squares 
indicate upregulation of this feature in a condition, green squares indicate downregulation.
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 Supplemental 
Fig. 10: Variable Importance in Projection (VIP) of ANP-MS positive mode. VIP scores indicate the 
importance of a variable in projection using a PLS DA model. VIP-scores > 1 can be considered as 
good variables in a given model. All features shown are also differential. Red squares indicate 
upregulation of this feature in a condition, green squares indicate downregulation. 
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Supplemental Fig. 11: Variable Importance in Projection (VIP) of ANP-MS negative mode. VIP scores 
indicate the importance of a variable in projection using a PLS DA model. VIP-scores > 1 can be 
considered as good variables in a given model. None of the features shown are differential. Red 
squares indicate upregulation of this feature in a condition, green squares indicate downregulation. 
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Supplemental Fig. 12: Volcano plot from GC-MS mode. X-axis represents the fold change, ions with a fold 
change >±2 are selected. Y-axis represents the p value (adjusted according to the Benjamini & Hochberg 
principle), ions with p value<0.05 are selected. Red and blue dots represent ions which are respectively 
significantly upregulated and downregulated. 
 
Supplemental Fig. 13: Volcano plot from RP-MS positive mode. X-axis represents the fold change, ions 
with a fold change >±2 are selected. Y-axis represents the p value (adjusted according to the Benjamini & 
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Hochberg principle), ions with p value<0.05 are selected. Red and blue dots represent ions which are 
respectively significantly upregulated and downregulated. 
 
Supplemental Fig. 14: Volcano plot from RP-MS negative mode. X-axis represents the fold change, ions 
with a fold change >±2 are selected. Y-axis represents the p value (adjusted according to the Benjamini & 
Hochberg principle), ions with p value<0.05 are selected. Red and blue dots represent ions which are 
respectively significantly upregulated and downregulated.
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Supplemental Fig. 15: Volcano plot from ANP-MS positive mode. X-axis represents the fold change, ions 
with a fold change >±2 are selected. Y-axis represents the p value, ions with p value<0.05 are selected. 
Red and blue dots represent ions which are respectively significantly upregulated and downregulated. 
 
Supplemental Fig. 16: Volcano plot from ANP-MS negative mode. X-axis represents the fold change, ions 
with a fold change >±2 are selected. Y-axis represents the p value (adjusted according to the Benjamini & 
Hochberg principle), ions with p value<0.05 are selected. Red and blue dots represent ions which are 
respectively significantly upregulated and downregulated. 
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Supplemental Fig. 17: Mass spectra of unknown differential GC-MS features. The number in the upper 
right corner corresponds to the mass identifiers. 
 
 
Supplemental Fig. 18: Comparison of common features in ANP and RP modes in negative ion mode  
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Supplemental Table 1: Average mass accuracy deviation from internal standards in different LC-MS modes. 
This average deviation ensures the reproducibility over longer periods of running samples. 
Average mass accuracy deviation 
Method ion mode Δppm 
LC-MS:RP + 1.49 
LC-MS:RP - 1.25 
LC-MS:ANP + 1.78 
LC-MS:ANP - 0.32 
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Supplemental Table 2: Mean and standard deviation of all samples in all modes. 
 Method 
Sample 
GC-MS ANP Q-TOF negative ANP Q-TOF positive 
 
RP Q-TOF negative RP Q-TOF positive 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Alzheimer 1 0.289218 2.193592 -0.05821 2.434255 0.078918 2.387719 0.188092 2.313494 -0.1192 2.589902 
Alzheimer 2 0.066625 2.431685 0.045026 2.338939 0.107688 2.422912 0.248602 2.248038 -0.12889 2.525678 
Alzheimer 3 0.027113 2.150899 -0.06346 2.573925 0.071822 2.468753 0.176934 2.45337 -0.11701 2.487699 
Alzheimer 4 0.038008 2.073683 0.10108 2.440149 0.037176 2.525653 0.219542 2.39715 -0.18061 2.587542 
Alzheimer 5 -0.24049 2.233567 0.093079 2.452153 -0.05332 2.761946 0.171522 2.449395 -0.17355 2.541348 
Alzheimer 6 0.140631 2.127284 0.095642 2.514082 0.016102 2.686503 0.185053 2.483518 -0.15573 2.614462 
Alzheimer 7 -0.0091 2.15554 -0.19676 2.749264 -0.09665 2.70039 0.193727 2.367049 -0.14612 2.527806 
Alzheimer 8 -0.09595 1.886018 -0.05752 2.536706 -0.01936 2.597872 0.190346 2.431482 -0.1707 2.596611 
Alzheimer 9 -0.09273 2.244538 -0.00544 2.521075 0.013408 2.57334 x x -0.16053 2.528764 
Alzheimer 10 0.149282 2.422314 -0.04272 2.756837 -0.05756 2.740538 0.155196 2.426959 -0.14313 2.578261 
Alzheimer 11 0.114088 2.17637 -0.09886 2.639712 0.011105 2.612182 0.212485 2.408747 -0.14173 2.599665 
Alzheimer 12 -0.01567 2.288362 -0.05453 2.51674 0.042291 2.514518 0.165994 2.42117 -0.13226 2.534345 
Alzheimer 13 0.197501 2.148396 -0.17502 2.846281 -0.10136 2.928599 0.138847 2.543522 x x 
Alzheimer 14 0.268837 2.233179 -0.19133 2.965841 -0.12945 2.856533 0.169206 2.576116 -0.09104 2.556176 
Control 1 0.118745 2.085829 0.022472 2.924574 -0.08687 2.781249 0.31142 3.008081 -0.00045 2.66725 
Control 2 0.099936 2.203378 -0.03341 2.724515 -0.03485 2.749882 0.276245 2.602968 -0.07955 2.555801 
Control 3 0.489007 2.065365 -0.08008 2.70035 0.012973 2.55323 0.263156 2.509007 -0.12766 2.609946 
Control 4 0.464009 2.299375 -0.06268 2.749366 -0.03541 2.759343 0.220962 2.461584 -0.1352 2.604168 
Control 5 -0.02621 2.383478 0.061814 2.66521 -0.09455 2.843686 0.226446 2.607527 -0.11119 2.610994 
Control 6 0.108725 2.107454 0.058593 2.648245 -0.01464 2.77811 0.201352 2.435736 -0.14075 2.536046 
Control 7 -0.02777 2.475253 0.043967 2.911033 0.021338 2.778744 0.232835 2.833303 0.028768 2.645141 
Control 8 0.213967 2.150101 0.106957 2.696244 0.04575 2.578497 0.227922 2.722791 0.058015 2.643619 
Control 9 -0.22721 2.354703 -0.13964 3.160766 -0.24699 3.116861 0.130245 2.549842 -0.13243 2.555988 
Control 10 -0.40613 2.839733 x x -0.27489 3.170641 0.079321 2.4582 -0.17093 2.52641 
Control 11 0.196368 2.330416 x x 0.028957 2.624169 0.269518 2.668004 0.183354 2.752695 
Control 12 0.048334 2.098936 0.011495 2.813628 -0.01154 2.688402 0.191693 2.665898 -0.08764 2.574055 
Control 13 -0.0174 2.315875 -0.26465 2.939879 -0.15786 2.834979 0.169733 2.529776 -0.09384 2.56488 
Control 14 0.152169 2.369799 -0.20765 3.044097 -0.25134 3.04504 0.154241 2.64557 -0.04589 2.546521 
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Supplemental Table 3: Significant differential features combined from different modes. Mass, retention 
time, p value (*adjusted according to the Benjamini & Hochberg principle), fold change, ion mode and 
putative confirmation of those metabolites in literature are shown. Adducts indicated with same 
superscript number. 
LC-MS differential features 
Mass (m/z) RT p value* Fold change Mode Putative confirmation literature 
173.1108 3.1 0.0017 2.11 ANP+  
131.1159 7.0 0.0017 4.76 ANP+  
169.0724 7.0 0.0017 3.21 ANP+  
230.1783 8.1 0.0017 7.92 ANP+  
131.1159 7.1 0.0026 4.42 ANP+  
384.1027 1.4 0.0037 0.57 RP-  
509.3433 12.4 0.0037 9.54 RP- Lin et al. 2013 
929.6274
1 
11.6 0.0038 15.77 RP-  
366.1274 12.7 0.0050 9.96 RP-  
929.8786 3.8 0.0050 4.03 RP-  
464.5713
1 
11.6 0.0050 5.48 RP-  
114.0901 0.8 0.0052 2.91 RP+  
448.2284 9.7 0.0052 2.35 RP+  
131.1167 0.8 0.0061 3.56 RP+  
362.2059 8.8 0.0061 2.56 RP+  
131.2164 0.8 0.0061 2.72 RP+  
485.1334 4.4 0.0061 7.21 RP+  
516.0773 3.7 0.0061 3.87 RP+  
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131.0899 0.8 0.0068 2.85 RP+  
397.2089 8.5 0.0068 3.35 RP+  
173.1239 3.0 0.0084 3.39 ANP+  
449.1221 8.0 0.0096 6.72 RP-  
929.3781 3.9 0.0125 3.54 RP-  
219.0865 2.3 0.0131 5.67 RP-  
386.1452 4.7 0.0131 2.16 RP- Trushina et al. 2013 
721.1036 3.5 0.0131 3.03 RP-  
559.1440 7.6 0.0131 2.71 RP-  
482.3108 11.2 0.0134 6.65 RP-  
188.2915 11.3 0.0138 3.75 ANP+  
466.3274
1 
11.6 0.0141 13.30 RP-  
337.1427 11.2 0.0141 1.79 RP-  
505.1993 5.8 0.0145 0.53 ANP+  
409.0493 6.4 0.0145 0.49 ANP+  
549.1047 6.4 0.0145 0.44 ANP+  
120.0793 2.8 0.0145 2.09 ANP+  
961.6186
2 
11.3 0.0150 22.27 RP-  
914.5292 10.0 0.0150 6.12 RP-  
787.2068 5.3 0.0150 2.46 RP-  
449.1218 7.6 0.0150 8.17 RP-  
608.1493 8.9 0.0150 0.55 RP-  
582.3737
3 
11.8 0.0150 8.75 RP-  
480.4946
2 
11.3 0.0150 14.31 RP-  
45 
 
347.1713 11.2 0.0151 1.46 RP- Lin et al. 2013 
650.2202 7.2 0.0160 10.80 RP+  
348.0537 1.0 0.0161 2.88 RP-  
951.3460 6.3 0.0166 4.76 RP-  
886.5142 12.7 0.0166 6.94 RP-  
755.2796 6.1 0.0166 7.70 RP-  
188.1732 11.6 0.0174 3.03 ANP+  
858.4997 5.4 0.0174 4.16 ANP+  
840.4818 7.4 0.0174 8.13 ANP+  
566.2537 11.6 0.0174 12.36 RP-  
607.2028 7.2 0.0174 3.73 RP-  
902.5655 2.7 0.0180 9.49 ANP+  
454.2554 8.6 0.0180 0.31 RP-  
376.1198 4.5 0.0182 3.19 RP-  
525.1274 4.6 0.0182 2.73 RP-  
618.2788 10.0 0.0187 0.38 RP-  
339.1420 11.2 0.0187 2.28 RP- Trushina et al. 2013 
271.2258 12.0 0.0190 0.66 RP-  
521.2149 6.3 0.0190 5.78 RP-  
220.0761 11.5 0.0190 4.04 RP-  
188.1730 11.0 0.0193 3.53 ANP+  
627.3304 9.8 0.0196 2.33 RP-  
828.5257 6.0 0.0199 7.57 ANP+  
667.1847 3.9 0.0201 1.93 RP-  
46 
 
359.0209 3.4 0.0201 0.35 RP-  
482.3122 11.3 0.0201 5.86 RP-  
494.3246 11.7 0.0201 13.04 RP-  
929.3780 3.8 0.0201 3.22 RP-  
466.3256 11.8 0.0201 6.48 RP-  
543.2429 10.1 0.0204 0.55 RP-  
667.1856 3.5 0.0208 3.73 RP-  
614.3279 9.4 0.0208 0.61 RP-  
493.1857 9.1 0.0208 0.51 RP-  
270.2132 5.8 0.0212 0.35 ANP+  
1056.3666 7.3 0.0219 16.43 RP-  
350.0537 1.3 0.0228 2.16 RP-  
856.4912 5.0 0.0232 2.45 ANP+  
113.1056 11.2 0.0238 0.27 ANP+  
702.3237 8.0 0.0241 6.23 RP-  
671.3998 5.5 0.0241 2.29 ANP-  
824.4982 7.7 0.0242 5.98 ANP+  
824.5092 7.5 0.0242 5.77 ANP+  
1012.5129 6.2 0.0242 9.13 ANP+  
723.2497 7.2 0.0246 2.80 RP-  
494.3233
4 
11.5 0.0246 8.19 RP-  
659.1859 4.1 0.0257 2.85 RP-  
559.0438
5 
0.7 0.0258 0.38 RP-  
464.3112 11.7 0.0258 5.17 RP-  
47 
 
159.0297 1.2 0.0258 0.26 RP-  
199.0365 0.9 0.0258 0.27 RP-  
342.1580 4.5 0.0259 2.22 RP+  
480.3387
3 
11.8 0.0266 8.33 RP-  
626.3630 11.3 0.0266 4.05 RP-  
306.0758 0.8 0.0280 0.18 RP-  
101.0243 1.0 0.0280 0.28 RP-  
438.4403 10.0 0.0280 10.43 RP-  
490.3248 11.1 0.0280 2.30 RP-  
840.4828 7.2 0.0293 8.30 ANP+  
849.5176 6.2 0.0299 10.43 ANP+  
436.2475 6.5 0.0299 5.81 ANP+  
1190.6154 6.1 0.0299 14.09 ANP+  
328.0459 1.6 0.0303 1.63 RP-  
933.6609 11.6 0.0307 17.07 RP+  
931.6426 11.6 0.0311 18.71 RP-  
478.3177 11.3 0.0311 4.91 RP-  
298.1658 6.4 0.0314 0.55 ANP+  
461.1953 9.3 0.0314 0.78 RP-  
548.2950 11.3 0.0314 3.60 RP-  
658.2943 9.4 0.0314 0.45 RP-  
487.1361 0.8 0.0314 0.19 RP-  
597.0578 4.6 0.0317 1.89 RP-  
780.3302 9.1 0.0317 0.13 RP-  
48 
 
462.1519 5.7 0.0317 6.11 RP-  
572.3035 9.3 0.0317 2.56 RP-  
496.3387
4 
11.5 0.0342 3.54 RP-  
660.1303 6.4 0.0364 0.43 ANP+  
848.5050 6.0 0.0364 8.37 ANP+  
626.3276 10.0 0.0379 1.90 RP-  
874.3086 8.2 0.0379 0.50 RP-  
199.0354 0.9 0.0385 0.30 RP-  
580.2341
6 
11.2 0.0385 4.58 RP-  
541.1447
 
0.7 0.0385 0.36 RP-  
360.2733 10.8 0.0385 0.57 RP-  
987.6298 10.7 0.0385 5.82 RP-  
640.2898
7 
11.4 0.0385 3.42 RP- Lin et al. 2013 
514.0620 3.7 0.0385 6.89 RP-  
554.3787 11.7 0.0385 7.65 RP-  
478.3222 12.2 0.0385 5.45 RP-  
570.3637
7 
11.4 0.0385 5.23 RP-  
215.1592 0.7 0.0388 2.12 RP-  
313.0481 1.0 0.0396 0.30 RP-  
760.2077 5.3 0.0406 4.38 RP-  
831.5874 11.8 0.0406 0.03 RP-  
938.3802 3.2 0.0412 2.32 RP-  
587.2211 4.6 0.0412 3.63 RP-  
526.0336 3.9 0.0412 0.68 RP-  
49 
 
623.1998 6.2 0.0412 5.01 RP-  
478.3202 12.0 0.0421 5.11 RP-  
480.3091
2 
11.3 0.0421 5.94 RP-  
596.1314 1.3 0.0421 2.02 RP-  
180.2259 1.3 0.0421 1.64 RP-  
481.3090
6 
11.2 0.0421 4.79 RP-  
341.0660 4.4 0.0421 0.36 RP-  
886.5147 12.6 0.0421 3.59 RP-  
481.2605 11.3 0.0421 0.25 RP-  
997.5264 10.0 0.0421 4.45 RP-  
524.2846 11.6 0.0421 5.11 RP-  
558.2669 8.3 0.0421 0.41 RP-  
556.0887 4.6 0.0421 0.22 RP-  
398.1538 11.2 0.0421 1.86 RP-  
945.5858 10.8 0.0421 5.59 RP-  
506.1160 5.6 0.0422 5.57 RP-  
520.0780 6.4 0.0440 0.47 ANP+  
762.4840 4.5 0.0440 4.00 ANP+  
736.4611 4.5 0.0440 3.36 ANP+  
864.4734 6.1 0.0440 5.85 ANP+  
180.0657 1.3 0.0446 1.36 RP-  
265.1475 11.1 0.0446 0.57 RP-  
524.2976 13.9 0.0446 3.19 RP-  
465.1534
8 
8.2 0.0446 0.62 RP-  
50 
 
354.0735 0.7 0.0446 1.38 RP-  
492.3428 11.8 0.0446 6.32 RP-  
650.2569 6.0 0.0446 6.07 RP-  
166.0194
5 
0.7 0.0446 18.94 RP-  
480.3403 12.2 0.0446 8.32 RP-  
897.2883 7.5 0.0446 5.08 RP-  
592.3576 11.0 0.0446 2.54 RP-  
495.3247 11.7 0.0446 7.67 RP-  
668.2849
7 
11.4 0.0446 4.18 RP-  
405.2181 5.8 0.0446 2.68 RP- Lin et al. 2013 
466.1571
8 
8.2 0.0446 0.54 RP-  
653.1407 1.0 0.0446 0.21 RP-  
162.8385 10.3 0.0447 0.48 RP-  
438.0753 6.4 0.0447 0.47 ANP+  
931.5152 6.3 0.0447 11.43 ANP+  
798.4845 5.8 0.0447 3.44 ANP+  
975.5311 6.4 0.0447 7.25 ANP+  
551.3549 1.5 0.0447 1.66 ANP+  
244.1892 1.7 0.0467 0.43 ANP+  
850.5135 8.0 0.0467 5.34 ANP+  
632.1628 5.3 0.0473 6.80 RP+  
822.6104 11.4 0.0474 4.06 RP-  
440.3903 10.7 0.0475 2.80 RP+  
931.6479 11.6 0.0475 11.86 RP+  
51 
 
161.1369 0.3 0.0477 0.54 RP+  
 
  
52 
 
Supplemental Table 4: Accurate mass of tyrosine using Q Exactive Hybrid Quadrupole-Orbitrap mass 
spectrometer. Accurate mass (m/z value), p value (*adjusted according to the Benjamini & Hochberg 
principle), fold change, ion mode, Δppm and identification are shown. 
Accurate mass differential features LC-MS 
Mass (m/z) Accurate mass p value* Fold change Mode Δppm Identification 
180.065 180.0665 0.0446 1.36 RP- 0 Tyrosine  
 
 
